Patents by Inventor Russell B. Lingham
Russell B. Lingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6541515Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The culture Cytospora sp. MF 6608 (ATCC PTA-1691) is also disclosed, as well as processes for making a compound of the present invention employing the culture.Type: GrantFiled: August 9, 2001Date of Patent: April 1, 2003Assignee: Merck & Co., Inc.Inventors: Sheo Bux Singh, Hiranthi Jayasuriya, Ziqiang Guan, Keith C. Silverman, Russell B. Lingham, Anne W. Dombrowski, Daria J. Hazuda, Jon D. Polishook
-
Patent number: 6403347Abstract: Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: October 25, 1999Date of Patent: June 11, 2002Assignee: Merck & Co., Inc.Inventors: Gerald F. Bills, Russell B. Lingham, Ali Shafiee, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink, Fernando Pelaez, Ana M. Teran
-
Publication number: 20020045658Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The culture Cytospora sp. MF 6608 (ATCC PTA-1691) is also disclosed, as well as processes for making a compound of the present invention employing the culture.Type: ApplicationFiled: August 9, 2001Publication date: April 18, 2002Inventors: Sheo Bux Singh, Hiranthi Jayasuriya, Ziqiang Guan, Keith C. Silverman, Russell B. Lingham, Anne W. Dombrowski, Daria J. Hazuda, Jon D. Polishook
-
Patent number: 6124327Abstract: Natural products such as certain dimerized hydroxyphenylundecanes are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: July 27, 1998Date of Patent: September 26, 2000Assignee: Merck & Co., Inc.Inventors: Keith C. Silverman, Russell B. Lingham, Sheo Bux Singh, Deborah L. Zink, Ana Teran
-
Patent number: 6110716Abstract: Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: February 4, 1998Date of Patent: August 29, 2000Assignee: Merck & Co., Inc.Inventors: Russell B. Lingham, Ali Shafiee, Keith C. Silverman, Ana M. Teran, Sheo Bux Singh, Deborah L. Zink
-
Patent number: 5858738Abstract: Natural products such as certain ermophilane sesquiterpenoids and derivatives thereof are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The fungal culture MF6254, Xylaria sp. (ATCC 74397) is also described and disclosed.Type: GrantFiled: November 4, 1997Date of Patent: January 12, 1999Assignee: Merck & Co., Inc.Inventors: Russell B. Lingham, Jon David Polishook, Ali Shafiee, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink
-
Patent number: 5789438Abstract: The present invention is directed to steroidal or terpenoidal compounds which inhibit farnesyl-protein transferase (FPTase). The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.Type: GrantFiled: September 5, 1997Date of Patent: August 4, 1998Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, Russell B. Lingham, Keith C. Silverman, Deborah L. Zink, Isabel Martin, Fernando Pelaez, Manuel Sanchez
-
Patent number: 5703067Abstract: The present invention is directed to steroidal or terpenoidal compounds which inhibit farnesyl-protein transferase (FPTase). The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.Type: GrantFiled: May 8, 1995Date of Patent: December 30, 1997Assignee: Merck & Co., Inc.Inventors: Hiranthi Jayasuriya, Russell B. Lingham, Fernando Pelaez, Manuel Sanchez, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink
-
Patent number: 5663193Abstract: The present invention is directed to non-peptide compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention also relates to the process for the preparation of a compound of this invention by cultivating a culture of Phoma sp. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: July 17, 1996Date of Patent: September 2, 1997Assignee: Merck & Co., Inc.Inventors: Carmen Cascales, Russell B. Lingham, Fernando Pelaez, Jon D. Polishook, Keith C. Silverman, Sheo B. Singh, Deborah L. Zink
-
Patent number: 5627057Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. Furthermore, Actinoplanes sp. ATCC 55532 and Streptomces sp. ATCC 55550 are microorganisms which are capable of producing the disclosed compounds which are classified as carboxylic acid esters. In addition a method for preparing the compounds is disclosed which includes cultivating strain ATCC 55532 or strain ATCC 55550. The strains are independently capable of producing the carboxylic acid ester compounds.Type: GrantFiled: March 6, 1996Date of Patent: May 6, 1997Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, George M. Garrity, Olga Genillourd, Russell B. Lingham, Isabel Martin, Mary Nallin-Omstead, Keith C. Silverman, Deborah L. Zink
-
Patent number: 5510371Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: June 6, 1994Date of Patent: April 23, 1996Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, George M. Garrity, Olga Genillourd, Russell B. Lingham, Isabel Martin, Mary N. Omstead, Keith C. Silverman, Deborah L. Zink
-
Patent number: 5436263Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: March 22, 1994Date of Patent: July 25, 1995Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, Barry A. Katz, Russell B. Lingham, Isabel Martin, Keith C. Silverman
-
Patent number: 5420157Abstract: This invention relates to pharmaceutical compounds of structural formulae (I) and (II): ##STR1## and compositions and methods of treatment utilizing these compounds to inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras.Type: GrantFiled: December 16, 1991Date of Patent: May 30, 1995Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, Gerald F. Bills, Russell B. Lingham, Keith C. Silverman, Deborah L. Zink
-
Patent number: 5420334Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting famesyl-protein transferase and the famesylation of the oncogene protein Ras.Type: GrantFiled: April 4, 1994Date of Patent: May 30, 1995Assignee: Merck & Co., Inc.Inventors: Sheo B. Singh, Gerald F. Bills, Russell B. Lingham, Isabel Martin, Keith C. Silverman, Jack L. Smith
-
Patent number: 5283256Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).Type: GrantFiled: July 22, 1992Date of Patent: February 1, 1994Assignee: Merck & Co., Inc.Inventors: Claude Dufresne, Josep Guarro, Leeyuan Huang, Yu L. Kong, Russell B. Lingham, Maria S. Meinz, Keith C. Silverman, Sheo B. Singh
-
Patent number: 5250563Abstract: Novel cytochalasins are the biotransformed products after incubation with a substrate in a culture of the microorganism Kibdelosporangium sp. (Merck Culture Collection MA 6559), ATCC No. 53771. The compounds of the present invention inhibit HIV protease and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.Type: GrantFiled: September 25, 1992Date of Patent: October 5, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, George A. Doss, Russell B. Lingham
-
Patent number: 5192668Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: February 27, 1992Date of Patent: March 9, 1993Assignee: Merck & Co., Inc.Inventors: Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
-
Patent number: 5187074Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: February 20, 1992Date of Patent: February 16, 1993Assignee: Merck & Co., Inc.Inventors: Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
-
Patent number: 5183826Abstract: An antiviral agent produced by Hypoxylon fragiforme and having the structure: ##STR1## is described. The product has high activity as an HIV protease enzyme inhibitor and is useful in the treatment of diseases in which control of HIV protease activity is desirable.Type: GrantFiled: September 25, 1990Date of Patent: February 2, 1993Assignee: Merck & Co., Inc.Inventors: Gerald F. Bills, Otto D. Hensens, Lawrence Koupal, Russell B. Lingham, John G. Ondeyka, Deborah L. Zink